Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who
have esophageal or stomach cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI) Pharmacia and Upjohn